<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Radiol</journal-id><journal-title-group><journal-title>European Radiology</journal-title></journal-title-group><issn pub-type="ppub">0938-7994</issn><issn pub-type="epub">1432-1084</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21953376</article-id><article-id pub-id-type="pmc">3269572</article-id><article-id pub-id-type="publisher-id">2288</article-id><article-id pub-id-type="doi">10.1007/s00330-011-2288-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Contrast Media</subject></subj-group></article-categories><title-group><article-title>MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Brismar</surname><given-names>Torkel B.</given-names></name><address><phone>+46-8-58584692</phone><fax>+46-8-7114840</fax><email>torkel.brismar@karolinska.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kartalis</surname><given-names>Nikolaos</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kylander</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Albiin</surname><given-names>Nils</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden </aff><aff id="Aff2"><label>2</label>Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>9</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>9</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2012</year></pub-date><volume>22</volume><issue>3</issue><fpage>633</fpage><lpage>641</lpage><history><date date-type="received"><day>21</day><month>5</month><year>2011</year></date><date date-type="rev-recd"><day>24</day><month>8</month><year>2011</year></date><date date-type="accepted"><day>12</day><month>9</month><year>2011</year></date></history><permissions><copyright-statement>© The Author(s) 2011</copyright-statement></permissions><abstract id="Abs1"><sec><title><offsets xml_i="2915" xml_f="2925" txt_i="11" txt_f="21">Objectives</offsets></title><p><offsets xml_i="2936" xml_f="3217" txt_i="22" txt_f="303">To compare the sensitivity of MRI to detect colorectal cancer liver metastases (CRLM) after ingestion of manganese-based contrast agent (CMC-001) with that of a comprehensive intravenous gadobenate dimeglumine protocol, and to assess the safety and acceptability of oral manganese.</offsets></p></sec><sec><title><offsets xml_i="3239" xml_f="3246" txt_i="305" txt_f="312">Methods</offsets></title><p><offsets xml_i="3257" xml_f="3791" txt_i="313" txt_f="847">20 patients suspected of having 1–6 CRLM were included prospectively in this randomised cross-over study. Liver MRI was performed with a one-week interval at 1.5 T and included T1-w VIBE and T2-HASTE, before and after administration of 1.6 g CMC-001 or 0.1 mmol/kg gadobenate dimeglumine. The metastasis-to-liver signal intensity (SI) ratio was calculated. Standard of reference was histopathology after surgery, or combination of other imaging studies and/or follow up. Adverse events (AE) and clinicolaboratory tests were monitored.</offsets></p></sec><sec><title><offsets xml_i="3813" xml_f="3820" txt_i="849" txt_f="856">Results</offsets></title><p><offsets xml_i="3831" xml_f="4156" txt_i="857" txt_f="1182">Of 44 metastases, 41 were detected after CMC-001 (93%) and 42 after gadobenate dimeglumine (95%). Fifteen false–positive lesions were found after CMC-001 and 2 after gadobenate dimeglumine. The metastasis-to-liver SI ratio was significantly higher after CMC-001 than after gadobenate dimeglumine (0.51 and 0.21 respectively, </offsets><italic><offsets xml_i="4164" xml_f="4165" txt_i="1182" txt_f="1183">P</offsets></italic><offsets xml_i="4174" xml_f="4257" txt_i="1183" txt_f="1263"> &lt; 0.0001). More AE occurred after manganese compared to gadobenate dimeglumine.</offsets></p></sec><sec><title><offsets xml_i="4279" xml_f="4290" txt_i="1265" txt_f="1276">Conclusions</offsets></title><p><offsets xml_i="4301" xml_f="4481" txt_i="1277" txt_f="1457">CMC-001 is as sensitive as an extensive intravenous gadobenate dimeglumine protocol in detecting CRLM. It was relatively well tolerated but had higher rates of gastrointestinal AE.</offsets></p></sec><sec><title><offsets xml_i="4503" xml_f="4513" txt_i="1459" txt_f="1469">Key Points</offsets></title><p><offsets xml_i="4524" xml_f="4526" txt_i="1470" txt_f="1472">• </offsets><italic><offsets xml_i="4534" xml_f="4617" txt_i="1472" txt_f="1555">Liver MRI after ingestion of manganese is highly sensitive for detecting metastases</offsets></italic></p><p><italic><offsets xml_i="4641" xml_f="4714" txt_i="1556" txt_f="1629">• High false–positive rate necessitates further evaluation, in some cases</offsets></italic></p><p><offsets xml_i="4730" xml_f="4732" txt_i="1630" txt_f="1632">• </offsets><italic><offsets xml_i="4740" xml_f="4772" txt_i="1632" txt_f="1664">The MR examination time is short</offsets></italic></p><p><italic><offsets xml_i="4796" xml_f="4878" txt_i="1665" txt_f="1747">• Oral ingestion of manganese seems safe and relatively well tolerated by patients</offsets></italic></p><p><italic><offsets xml_i="4902" xml_f="4995" txt_i="1748" txt_f="1841">• Manganese compounds may be useful for liver metastasis surveillance after colorectal cancer</offsets></italic></p></sec></abstract><kwd-group><title>Keywords</title><kwd>Magnetic resonance imaging</kwd><kwd>Liver</kwd><kwd>Neoplasm metastasis</kwd><kwd>Colorectal neoplasm</kwd><kwd>Contrast media</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© European Society of Radiology 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="5435" xml_f="5447" txt_i="1850" txt_f="1862">Introduction</offsets></title><p><offsets xml_i="5458" xml_f="5704" txt_i="1863" txt_f="2109">The liver is the most common site of metastases from the gastrointestinal tract, including pancreatic, gastric, small bowel, and colorectal cancers. In surveillance for liver metastases, the primary imaging technique is computed tomography (CT) [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="5736" xml_f="5737" txt_i="2109" txt_f="2110">1</offsets></xref><offsets xml_i="5744" xml_f="5746" txt_i="2110" txt_f="2112">, </offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="5778" xml_f="5779" txt_i="2112" txt_f="2113">2</offsets></xref><offsets xml_i="5786" xml_f="5852" txt_i="2113" txt_f="2179">]. Contrast-enhanced ultrasound is also reported to perform well [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="5884" xml_f="5885" txt_i="2179" txt_f="2180">3</offsets></xref><offsets xml_i="5892" xml_f="6017" txt_i="2180" txt_f="2305">]. However, MRI due to its superior diagnostic sensitivity and specificity when evaluating liver lesions plays a major role [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="6049" xml_f="6050" txt_i="2305" txt_f="2306">4</offsets></xref><offsets xml_i="6057" xml_f="6059" txt_i="2306" txt_f="2308">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="6091" xml_f="6092" txt_i="2308" txt_f="2309">5</offsets></xref><offsets xml_i="6099" xml_f="6101" txt_i="2309" txt_f="2311">].</offsets></p><p><offsets xml_i="6108" xml_f="6595" txt_i="2312" txt_f="2799">To improve the detection and characterisation of lesions, a number of intravenous MRI contrast agents have been developed. Among these, two of the T1-shortening contrast agents have liver-specific characteristics: gadoxetic acid (Primovist®) and gadobenate dimeglumine (MultiHance®). These contrast agents have to be administered intravenously and contain gadolinium, which increases the risk of nephrogenic systemic fibrosis (NSF) in patients with low glomerular filtration rate (GFR) [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="6627" xml_f="6628" txt_i="2799" txt_f="2800">6</offsets></xref><offsets xml_i="6635" xml_f="6637" txt_i="2800" txt_f="2802">].</offsets></p><p><offsets xml_i="6644" xml_f="6921" txt_i="2803" txt_f="3080">A liver-specific contrast medium that is not administered intravenously and which does not contain gadolinium would be of great value for evaluating patients at high risk of liver metastases. A new contrast medium where the manganese is administered orally has been developed [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="6953" xml_f="6954" txt_i="3080" txt_f="3081">7</offsets></xref><offsets xml_i="6961" xml_f="6963" txt_i="3081" txt_f="3083">, </offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="6995" xml_f="6996" txt_i="3083" txt_f="3084">8</offsets></xref><offsets xml_i="7003" xml_f="7137" txt_i="3084" txt_f="3218">]. The uptake of manganese from the bowel is normally very limited, but can be facilitated when it is mixed with alanine and vitamin D</offsets><sub><offsets xml_i="7142" xml_f="7143" txt_i="3218" txt_f="3219">3</offsets></sub><offsets xml_i="7149" xml_f="7263" txt_i="3219" txt_f="3333">. The manganese is then extracted from the blood circulation by the liver and is subsequently excreted with bile [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="7295" xml_f="7296" txt_i="3333" txt_f="3334">9</offsets></xref><offsets xml_i="7303" xml_f="7304" txt_i="3334" txt_f="3335">–</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="7337" xml_f="7339" txt_i="3335" txt_f="3337">11</offsets></xref><offsets xml_i="7346" xml_f="7665" txt_i="3337" txt_f="3656">]. The high manganese uptake in the liver by the hepatocytes significantly decreases their T1 relaxation time, causing the liver parenchyma to appear bright on T1-weighted images. Non-functioning hepatocytes and metastases will not take up manganese and will therefore be of low signal intensity on T1-weighted images [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="7697" xml_f="7698" txt_i="3656" txt_f="3657">7</offsets></xref><offsets xml_i="7705" xml_f="7707" txt_i="3657" txt_f="3659">, </offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="7739" xml_f="7740" txt_i="3659" txt_f="3660">8</offsets></xref><offsets xml_i="7747" xml_f="7749" txt_i="3660" txt_f="3662">, </offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="7782" xml_f="7784" txt_i="3662" txt_f="3664">12</offsets></xref><offsets xml_i="7791" xml_f="7793" txt_i="3664" txt_f="3666">].</offsets></p><p><offsets xml_i="7800" xml_f="8139" txt_i="3667" txt_f="4006">The primary aim of this phase II trial was to evaluate whether the sensitivity of the new oral contrast medium to detect colorectal liver cancer metastases (CRLM) was comparable to that of a comprehensive intravenous gadobenate dimeglumine protocol. The secondary aim was to assess the safety and acceptability of this new agent (CMC-001).</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="8200" xml_f="8220" txt_i="4008" txt_f="4028">Material and methods</offsets></title><sec id="Sec3"><title><offsets xml_i="8250" xml_f="8286" txt_i="4029" txt_f="4065">Population and standard of reference</offsets></title><p><offsets xml_i="8297" xml_f="9274" txt_i="4066" txt_f="5043">Local ethics committee approval and informed patient consent were obtained for this open, randomised cross-over prospective study in which each patient constituted his/her own control. Twenty patients, 10 men and 10 women, aged 51–79 years (mean 64 years) were recruited prospectively and consecutively. All patients had been referred to the multidisciplinary team for evaluation of 1–6 suspected CRLMs before partial liver resection. The suspected metastases had been observed at contrast-enhanced CT in 17 patients and at MRI in 3 patients. In addition, nine of the patients had undergone a contrast-enhanced transabdominal ultrasound. At the final analysis (histopathology, additional imaging or follow-up) one or more metastases were found in 16 of the 20 patients; in 4 patients there were no metastases. In total, 44 metastases were identified (mean size: 19.5 mm, standard deviation: 15.6, size range: 3–73 mm). Metastases were verified at histopathology after surgery (</offsets><italic><offsets xml_i="9282" xml_f="9283" txt_i="5043" txt_f="5044">n</offsets></italic><offsets xml_i="9292" xml_f="9497" txt_i="5044" txt_f="5249"> = 25), at combined evaluation of contrast-enhanced ultrasound and gadobenate dimeglumine-enhanced MRI by a consensus committee consisting of radiologists and surgeons at the multidisciplinary conference (</offsets><italic><offsets xml_i="9505" xml_f="9506" txt_i="5249" txt_f="5250">n</offsets></italic><offsets xml_i="9515" xml_f="9586" txt_i="5250" txt_f="5321"> = 7), contrast-enhanced ultrasound performed at least 3 months later (</offsets><italic><offsets xml_i="9594" xml_f="9595" txt_i="5321" txt_f="5322">n</offsets></italic><offsets xml_i="9604" xml_f="9657" txt_i="5322" txt_f="5375"> = 8), intra-operative contrast-enhanced ultrasound (</offsets><italic><offsets xml_i="9665" xml_f="9666" txt_i="5375" txt_f="5376">n</offsets></italic><offsets xml_i="9675" xml_f="9721" txt_i="5376" txt_f="5422"> = 3) or contrast-enhanced CT 3 months later (</offsets><italic><offsets xml_i="9729" xml_f="9730" txt_i="5422" txt_f="5423">n</offsets></italic><offsets xml_i="9739" xml_f="10158" txt_i="5423" txt_f="5842"> = 1). The absence of metastatic lesion in four patients was confirmed by histopathology in two, by combined evaluation of contrast-enhanced ultrasound and gadobenate dimeglumine-enhanced MRI in one patient and, finally, by MDCT examination performed three months later in one patient. In these four patients, the suspected metastasis had been observed at CT in three patients and at gadoxetic acid enhanced MRI in one.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="10190" xml_f="10197" txt_i="5844" txt_f="5851">Imaging</offsets></title><p><offsets xml_i="10208" xml_f="10383" txt_i="5852" txt_f="6027">Two MRI examinations were performed on each patient at an interval of 1 week; orally administered manganese-based contrast medium CMC-001 (manganese chloride tetrahydrate MnCl</offsets><sub><offsets xml_i="10388" xml_f="10389" txt_i="6027" txt_f="6028">2</offsets></sub><offsets xml_i="10395" xml_f="10397" txt_i="6028" txt_f="6030">(H</offsets><sub><offsets xml_i="10402" xml_f="10403" txt_i="6030" txt_f="6031">2</offsets></sub><offsets xml_i="10409" xml_f="10411" txt_i="6031" txt_f="6033">O)</offsets><sub><offsets xml_i="10416" xml_f="10417" txt_i="6033" txt_f="6034">4</offsets></sub><offsets xml_i="10423" xml_f="10597" txt_i="6034" txt_f="6208">, CMC Contrast, Lyngby, Denmark) or intravenously administered gadobenate dimeglumine (MultiHance®, Bracco, Milan, Italy) was used in random order, based on sealed envelopes.</offsets></p><p><offsets xml_i="10604" xml_f="11155" txt_i="6209" txt_f="6760">The patients arrived at the MR unit early in the morning after one night of fasting. Imaging was performed at 1.5 T (Magnetom Avanto, Siemens Healthcare, Erlangen, Germany), combining the spine and the flexible body array coil before administration of contrast medium and either 3 h after oral ingestion of CMC-001 or after intravenous gadobenate dimeglumine using a 5-phase imaging protocol (unenhanced, arterioportal, portal venous, 5 min and 2 h), serving as our standard protocol in daily practice. The dose of CMC-001 was equivalent to 1.6 g MnCl</offsets><sub><offsets xml_i="11160" xml_f="11161" txt_i="6760" txt_f="6761">2</offsets></sub><offsets xml_i="11167" xml_f="11300" txt_i="6761" txt_f="6894"> and was dissolved in 200–400 mL of water. To facilitate its uptake, the manganese is combined with 1 g alanine and 1600 IU vitamin D</offsets><sub><offsets xml_i="11305" xml_f="11306" txt_i="6894" txt_f="6895">3</offsets></sub><offsets xml_i="11312" xml_f="11365" txt_i="6895" txt_f="6948">. The dose of gadobenate dimeglumine was 0.1 mmol/kg.</offsets></p><p><offsets xml_i="11372" xml_f="12032" txt_i="6949" txt_f="7609">For T1-weighted imaging, axial breath-hold 3D T1-weighted images [volumetric interpolated breath hold examination (VIBE), echo time (TE) 2.03–2.09 ms, repetition time (TR) 4.05–4.29 ms, field of view 40 cm and 120 1.8 mm thick slices] were obtained. For T2 imaging, 60 axial half-Fourier acquisition single-shot turbo spin-echo (HASTE) images with an echo time (TE) 76 ms, repetition time (TR) 1000 ms, field of view 38 × 28.5 cm and 4 mm thick slices) were used. Total MR examination time for CMC-001 session was about 10 min each for pre- and post-contrast imaging. At the gadobenate dimeglumine session, the total MR examination time was 60 + 10 min (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="12066" xml_f="12067" txt_i="7609" txt_f="7610">1</offsets></xref><offsets xml_i="12074" xml_f="12076" txt_i="7610" txt_f="7612">).</offsets><table-wrap id="Tab1"><label><offsets xml_i="12105" xml_f="12112" txt_i="7612" txt_f="7619">Table 1</offsets></label><caption><p><offsets xml_i="12132" xml_f="12197" txt_i="7619" txt_f="7684">The comprehensive protocol used when using gadobenate dimeglumine</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="12263" xml_f="12271" txt_i="7685" txt_f="7693">Sequence</offsets></th><th><offsets xml_i="12280" xml_f="12293" txt_i="7693" txt_f="7706">Imaging plane</offsets></th><th><offsets xml_i="12302" xml_f="12322" txt_i="7706" txt_f="7726">Slice thickness (mm)</offsets></th><th><offsets xml_i="12331" xml_f="12338" txt_i="7726" txt_f="7733">TE (ms)</offsets></th><th><offsets xml_i="12347" xml_f="12354" txt_i="7733" txt_f="7740">TR (ms)</offsets></th><th><offsets xml_i="12363" xml_f="12375" txt_i="7740" txt_f="7752">Imaging time</offsets></th><th><offsets xml_i="12384" xml_f="12391" txt_i="7752" txt_f="7759">Comment</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="12424" xml_f="12441" txt_i="7759" txt_f="7776">T2-weighted HASTE</offsets></td><td><offsets xml_i="12450" xml_f="12455" txt_i="7777" txt_f="7782">Axial</offsets></td><td><offsets xml_i="12464" xml_f="12465" txt_i="7783" txt_f="7784">4</offsets></td><td><offsets xml_i="12474" xml_f="12476" txt_i="7785" txt_f="7787">76</offsets></td><td><offsets xml_i="12485" xml_f="12489" txt_i="7788" txt_f="7792">1000</offsets></td><td><offsets xml_i="12498" xml_f="12503" txt_i="7793" txt_f="7798">3 min</offsets></td><td><offsets xml_i="12512" xml_f="12534" txt_i="7799" txt_f="7821">Respiratory triggering</offsets></td></tr><tr><td><offsets xml_i="12552" xml_f="12569" txt_i="7822" txt_f="7839">T2-weighted HASTE</offsets></td><td><offsets xml_i="12578" xml_f="12585" txt_i="7840" txt_f="7847">Coronal</offsets></td><td><offsets xml_i="12594" xml_f="12595" txt_i="7848" txt_f="7849">4</offsets></td><td><offsets xml_i="12604" xml_f="12606" txt_i="7850" txt_f="7852">76</offsets></td><td><offsets xml_i="12615" xml_f="12619" txt_i="7853" txt_f="7857">1080</offsets></td><td><offsets xml_i="12628" xml_f="12633" txt_i="7858" txt_f="7863">3 min</offsets></td><td><offsets xml_i="12642" xml_f="12664" txt_i="7864" txt_f="7886">Respiratory triggering</offsets></td></tr><tr><td><offsets xml_i="12682" xml_f="12691" txt_i="7887" txt_f="7896">True-FISP</offsets></td><td><offsets xml_i="12700" xml_f="12705" txt_i="7897" txt_f="7902">Axial</offsets></td><td><offsets xml_i="12714" xml_f="12715" txt_i="7903" txt_f="7904">4</offsets></td><td char="–" align="char"><offsets xml_i="12746" xml_f="12755" txt_i="7905" txt_f="7914">1.46–1.54</offsets></td><td char="–" align="char"><offsets xml_i="12786" xml_f="12795" txt_i="7915" txt_f="7924">3.43–3.61</offsets></td><td><offsets xml_i="12804" xml_f="12808" txt_i="7925" txt_f="7929">18 s</offsets></td><td><offsets xml_i="12817" xml_f="12828" txt_i="7930" txt_f="7941">Breath-hold</offsets></td></tr><tr><td><offsets xml_i="12846" xml_f="12855" txt_i="7942" txt_f="7951">True-FISP</offsets></td><td><offsets xml_i="12864" xml_f="12872" txt_i="7952" txt_f="7960">Sagittal</offsets></td><td><offsets xml_i="12881" xml_f="12882" txt_i="7961" txt_f="7962">4</offsets></td><td char="." align="char"><offsets xml_i="12913" xml_f="12917" txt_i="7963" txt_f="7967">1.38</offsets></td><td char="–" align="char"><offsets xml_i="12948" xml_f="12957" txt_i="7968" txt_f="7977">3.23–3.30</offsets></td><td><offsets xml_i="12966" xml_f="12970" txt_i="7978" txt_f="7982">18 s</offsets></td><td><offsets xml_i="12979" xml_f="12990" txt_i="7983" txt_f="7994">Breath-hold</offsets></td></tr><tr><td><offsets xml_i="13008" xml_f="13035" txt_i="7995" txt_f="8022">T1-weighted in/out of phase</offsets></td><td><offsets xml_i="13044" xml_f="13049" txt_i="8023" txt_f="8028">Axial</offsets></td><td><offsets xml_i="13058" xml_f="13059" txt_i="8029" txt_f="8030">4</offsets></td><td><offsets xml_i="13068" xml_f="13077" txt_i="8031" txt_f="8040">5.04/2.38</offsets></td><td><offsets xml_i="13086" xml_f="13089" txt_i="8041" txt_f="8044">126</offsets></td><td><offsets xml_i="13098" xml_f="13108" txt_i="8045" txt_f="8055">1 min 11 s</offsets></td><td><offsets xml_i="13117" xml_f="13139" txt_i="8056" txt_f="8078">Respiratory triggering</offsets></td></tr><tr><td><offsets xml_i="13157" xml_f="13161" txt_i="8079" txt_f="8083">MRCP</offsets></td><td><offsets xml_i="13170" xml_f="13175" txt_i="8084" txt_f="8089">Axial</offsets></td><td><offsets xml_i="13184" xml_f="13185" txt_i="8090" txt_f="8091">3</offsets></td><td><offsets xml_i="13194" xml_f="13197" txt_i="8092" txt_f="8095">678</offsets></td><td char="–" align="char"><offsets xml_i="13228" xml_f="13237" txt_i="8096" txt_f="8105">3339–8086</offsets></td><td><offsets xml_i="13246" xml_f="13251" txt_i="8106" txt_f="8111">3 min</offsets></td><td><offsets xml_i="13260" xml_f="13282" txt_i="8112" txt_f="8134">Respiratory triggering</offsets></td></tr><tr><td><offsets xml_i="13300" xml_f="13304" txt_i="8135" txt_f="8139">MRCP</offsets></td><td><offsets xml_i="13313" xml_f="13320" txt_i="8140" txt_f="8147">Coronal</offsets></td><td char="." align="char"><offsets xml_i="13351" xml_f="13354" txt_i="8148" txt_f="8151">1.5</offsets></td><td><offsets xml_i="13363" xml_f="13366" txt_i="8152" txt_f="8155">678</offsets></td><td char="–" align="char"><offsets xml_i="13397" xml_f="13407" txt_i="8156" txt_f="8166">3383–10546</offsets></td><td><offsets xml_i="13416" xml_f="13421" txt_i="8167" txt_f="8172">3 min</offsets></td><td><offsets xml_i="13430" xml_f="13452" txt_i="8173" txt_f="8195">Respiratory triggering</offsets></td></tr><tr><td rowspan="2"><offsets xml_i="13482" xml_f="13501" txt_i="8196" txt_f="8215">T1-weighted 3D VIBE</offsets></td><td rowspan="2"><offsets xml_i="13522" xml_f="13527" txt_i="8216" txt_f="8221">Axial</offsets></td><td char="." align="char" rowspan="2"><offsets xml_i="13570" xml_f="13573" txt_i="8222" txt_f="8225">1.8</offsets></td><td char="–" align="char" rowspan="2"><offsets xml_i="13616" xml_f="13625" txt_i="8226" txt_f="8235">2.03–2.09</offsets></td><td char="–" align="char" rowspan="2"><offsets xml_i="13668" xml_f="13677" txt_i="8236" txt_f="8245">4.05–4.29</offsets></td><td rowspan="2"><offsets xml_i="13698" xml_f="13702" txt_i="8246" txt_f="8250">22 s</offsets></td><td><offsets xml_i="13711" xml_f="13722" txt_i="8251" txt_f="8262">Breath-hold</offsets></td></tr><tr><td><offsets xml_i="13740" xml_f="13769" txt_i="8263" txt_f="8292">Before and after Gd-injection</offsets><sup><offsets xml_i="13774" xml_f="13775" txt_i="8292" txt_f="8293">1</offsets></sup></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="13832" xml_f="13833" txt_i="8294" txt_f="8295">1</offsets></sup><offsets xml_i="13839" xml_f="13909" txt_i="8295" txt_f="8365"> unenhanced, arterioportal, portal venous, 5 min and 2 h post-contrast</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="13951" xml_f="14252" txt_i="8367" txt_f="8668">In all cases of contrast-enhanced ultrasound, the microbubble-containing contrast agent sulphur hexafluoride (SonoVue®, Bracco, Milan, Italy) was injected in a single dose of 2.4 mg/ml followed by a flush of 5–10 ml isotonic saline; when needed, the injection was repeated to evaluate the whole liver.</offsets></p><p><offsets xml_i="14259" xml_f="14829" txt_i="8669" txt_f="9239">For patient safety, all examinations were evaluated at the time of the examination by one of the participating radiologists (N.A.) and the imaging findings were discussed at the multidisciplinary conference for decision-making. After a period of at least 6 weeks all examinations were re-evaluated in consensus by the two participating radiologists (N.A. and T.B.) for the purposes of the present study. The participating radiologists were aware that all patients had been referred for surgical procedure, but did not have access to previous studies or surgical outcome.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="14861" xml_f="14903" txt_i="9241" txt_f="9283">Image evaluation-lesion detection analysis</offsets></title><p><offsets xml_i="14914" xml_f="16576" txt_i="9284" txt_f="10946">The unenhanced series were first evaluated, then the corresponding contrast-enhanced series. In 10 patients, the CMC-enhanced examination was evaluated first; in the other 10, the comprehensive gadobenate dimeglumine examination was evaluated first. Irrespectively of order, the CMC-001 and the dimeglumine session were evaluated with an interval of at least 1 week. When evaluating CMC-enhanced images, both T1-weighted and T2-HASTE images were used. Criteria for the diagnosis of metastasis were low signal intensity at T1-weighted images and slightly high-signal intensity at T2-HASTE images. Criteria for classifying a lesion as non-metastatic (i.e. haemangioma or/and cyst) were low-signal intensity at T1-weighted images and markedly high-signal intensity at T2-HASTE images. When evaluating gadobenate dimeglumine-enhanced images, the whole comprehensive protocol was used. Criteria for the diagnosis of liver metastasis were slightly hyperintense appearance in the T2-HASTE series, discrete peripheral rim contrast enhancement in the arterial and/or portal venous phases, and hypointense appearance in the liver-specific phase of the contrast enhanced series (2 h after administration of contrast medium). Criteria for the diagnosis of haemangioma were presence of discontinuous nodular peripheral enhancement following intravenous contrast agent administration and markedly high-signal intensity at T2-HASTE series. Criteria for the diagnosis of cyst were absence of enhancement following intravenous contrast agent administration and markedly high-signal intensity at T2-HASTE series. The number of metastases and their greatest diameter were recorded.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="16608" xml_f="16646" txt_i="10948" txt_f="10986">Image evaluation-quantitative analysis</offsets></title><p><offsets xml_i="16657" xml_f="17318" txt_i="10987" txt_f="11648">The two participating radiologists (N.A. and T.B.) performed the quantitative analysis shortly after the lesion detection analysis was completed. There were two sets of unenhanced images of the liver: one before CMC-001 and one before gadobenate dimeglumine. For the calculations of lesion signal intensity before contrast-medium administration, the chronologically first of the two unenhanced series was used; for the calculations after contrast administration, only the hepatospecific phases were used (i.e. the T1-weighted image 3 h after ingestion of CMC-001 or the T1-weighted image 2 h after intravenous injection of gadobenate dimeglumine, respectively).</offsets></p><p><offsets xml_i="17325" xml_f="17667" txt_i="11649" txt_f="11991">The signal intensity of the metastasis was obtained from a centrally placed circular ROI with half the diameter of the metastasis. The signal intensity of the surrounding liver was obtained from a representative region near the metastasis, in the same image, on the same anteroposterior level. The metastasis-to-liver ratio was calculated as:</offsets><disp-formula id="Equa"><alternatives><tex-math id="M1"><offsets xml_i="17723" xml_f="18156" txt_i="11991" txt_f="12424">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\text{Metastasis to liver ratio}} = \frac{{{\text{Liver signal intensity}}--{\text{Metastasis signal intensity}}}}{\text{Liver signal intensity}} $$\end{document}</offsets></tex-math><graphic xlink:href="330_2011_2288_Article_Equa.gif" position="anchor"></graphic></alternatives></disp-formula></p></sec><sec id="Sec7"><title><offsets xml_i="18310" xml_f="18345" txt_i="12426" txt_f="12461">Safety and acceptability assessment</offsets></title><p><offsets xml_i="18356" xml_f="19125" txt_i="12462" txt_f="13231">Patients were carefully monitored for occurrence of AE at 1 and 2 h after contrast- medium administration and were additionally contacted by telephone at 24 and 48 h after each product administration for a follow-up of any ongoing or additional AE. AE were judged by the investigator as mild, moderate, or severe and those judged as having a reasonable causal relationship to the contrast agents qualified as adverse drug reactions (ADR). Other safety variables evaluated both before and at various time points after contrast-medium administration included clinical laboratory assessments (serum clinical chemistry, haematology, serology, urinalysis), vital signs (blood pressure and heart pulse rate), electrocardiogram (ECG) and physical examination (data not shown).</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="19157" xml_f="19167" txt_i="13233" txt_f="13243">Statistics</offsets></title><p><offsets xml_i="19178" xml_f="19220" txt_i="13244" txt_f="13286">The calculation was based on a one-sample </offsets><italic><offsets xml_i="19228" xml_f="19229" txt_i="13286" txt_f="13287">t</offsets></italic><offsets xml_i="19238" xml_f="19334" txt_i="13287" txt_f="13383">-test. Non-parametric tests were assessed by McNemar’s test (number of metastases after CMC-001 </offsets><italic><offsets xml_i="19342" xml_f="19344" txt_i="13383" txt_f="13385">vs</offsets></italic><offsets xml_i="19353" xml_f="19399" txt_i="13385" txt_f="13431">. unenhanced and after gadobenate dimeglumine </offsets><italic><offsets xml_i="19407" xml_f="19409" txt_i="13431" txt_f="13433">vs</offsets></italic><offsets xml_i="19418" xml_f="19526" txt_i="13433" txt_f="13541">. unenhanced). Parametric test (comparison of metastasis to liver ratio) was done by using Student’s paired </offsets><italic><offsets xml_i="19534" xml_f="19535" txt_i="13541" txt_f="13542">t</offsets></italic><offsets xml_i="19544" xml_f="19550" txt_i="13542" txt_f="13548">-test.</offsets></p></sec></sec><sec id="Sec9"><title><offsets xml_i="19588" xml_f="19595" txt_i="13551" txt_f="13558">Results</offsets></title><p><offsets xml_i="19606" xml_f="19708" txt_i="13559" txt_f="13661">At the unenhanced T1-weighted image series, 27 of 44 metastases were detected (sensitivity 61%, Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="19742" xml_f="19743" txt_i="13661" txt_f="13662">2</offsets></xref><offsets xml_i="19750" xml_f="19932" txt_i="13662" txt_f="13844">). After contrast-medium administration, a statistically significantly greater number of metastases were detected: after CMC-001, 41 of 44 metastases were detected (sensitivity 93%, </offsets><italic><offsets xml_i="19940" xml_f="19941" txt_i="13844" txt_f="13845">P</offsets></italic><offsets xml_i="19950" xml_f="20048" txt_i="13845" txt_f="13940"> &lt; 0.001) and after gadobenate dimeglumine 42 of 44 metastases were detected (sensitivity 95%, </offsets><italic><offsets xml_i="20056" xml_f="20057" txt_i="13940" txt_f="13941">P</offsets></italic><offsets xml_i="20066" xml_f="20085" txt_i="13941" txt_f="13957"> &lt; 0.001) (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="20117" xml_f="20118" txt_i="13957" txt_f="13958">1</offsets></xref><offsets xml_i="20125" xml_f="20356" txt_i="13958" txt_f="14189">). There was no statistically significant difference in the number of detected metastases between CMC-001 and gadobenate dimeglumine. There were more false–positive lesions detected at CMC-001 than at gadobenate dimeglumine (Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="20390" xml_f="20391" txt_i="14189" txt_f="14190">3</offsets></xref><offsets xml_i="20398" xml_f="20509" txt_i="14190" txt_f="14301">). A false–positive result for both CMC-001 and gadobenate dimeglumine-enhanced liver MRI is presented in Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="20541" xml_f="20542" txt_i="14301" txt_f="14302">2</offsets></xref><offsets xml_i="20549" xml_f="20642" txt_i="14302" txt_f="14395">, while a false–negative result for CMC-001 and gadobenate dimeglumine is presented on Figs. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="20674" xml_f="20675" txt_i="14395" txt_f="14396">3</offsets></xref><offsets xml_i="20682" xml_f="20687" txt_i="14396" txt_f="14401"> and </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="20719" xml_f="20720" txt_i="14401" txt_f="14402">4</offsets></xref><offsets xml_i="20727" xml_f="20874" txt_i="14402" txt_f="14549">, respectively. The mean metastasis-to-liver ratio increased from 0.22 (SD 0.16) before administration of contrast to 0.51 after CMC-001 (SD 0.17) </offsets><italic><offsets xml_i="20882" xml_f="20883" txt_i="14549" txt_f="14550">P</offsets></italic><offsets xml_i="20892" xml_f="21009" txt_i="14550" txt_f="14664"> &lt; 0.0001, but was unchanged after gadobenate dimeglumine [0.21 (SD 0.15) before and 0.21 (SD 0.09) after] (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="21043" xml_f="21044" txt_i="14664" txt_f="14665">4</offsets></xref><offsets xml_i="21051" xml_f="21053" txt_i="14665" txt_f="14667">).</offsets><table-wrap id="Tab2"><label><offsets xml_i="21082" xml_f="21089" txt_i="14667" txt_f="14674">Table 2</offsets></label><caption><p><offsets xml_i="21109" xml_f="21196" txt_i="14674" txt_f="14761">The number of liver metastases detected before and after contrast-medium administration</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="21271" xml_f="21281" txt_i="14762" txt_f="14772">Unenhanced</offsets></th><th><offsets xml_i="21290" xml_f="21297" txt_i="14772" txt_f="14779">CMC-001</offsets></th><th><offsets xml_i="21306" xml_f="21328" txt_i="14779" txt_f="14801">Gadobenate dimeglumine</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="21361" xml_f="21374" txt_i="14801" txt_f="14814">True positive</offsets></td><td><offsets xml_i="21383" xml_f="21385" txt_i="14815" txt_f="14817">27</offsets><sup><offsets xml_i="21390" xml_f="21391" txt_i="14817" txt_f="14818">a</offsets></sup></td><td><offsets xml_i="21406" xml_f="21408" txt_i="14819" txt_f="14821">41</offsets><sup><offsets xml_i="21413" xml_f="21414" txt_i="14821" txt_f="14822">b</offsets></sup></td><td><offsets xml_i="21429" xml_f="21431" txt_i="14823" txt_f="14825">42</offsets><sup><offsets xml_i="21436" xml_f="21437" txt_i="14825" txt_f="14826">c</offsets></sup></td></tr><tr><td><offsets xml_i="21461" xml_f="21475" txt_i="14827" txt_f="14841">False negative</offsets></td><td><offsets xml_i="21484" xml_f="21486" txt_i="14842" txt_f="14844">17</offsets></td><td><offsets xml_i="21495" xml_f="21496" txt_i="14845" txt_f="14846">3</offsets></td><td><offsets xml_i="21505" xml_f="21506" txt_i="14847" txt_f="14848">2</offsets></td></tr><tr><td><offsets xml_i="21524" xml_f="21538" txt_i="14849" txt_f="14863">False positive</offsets></td><td><offsets xml_i="21547" xml_f="21548" txt_i="14864" txt_f="14865">7</offsets></td><td><offsets xml_i="21557" xml_f="21559" txt_i="14866" txt_f="14868">15</offsets></td><td><offsets xml_i="21568" xml_f="21569" txt_i="14869" txt_f="14870">2</offsets></td></tr><tr><td><offsets xml_i="21587" xml_f="21602" txt_i="14871" txt_f="14886">Sensitivity (%)</offsets></td><td><offsets xml_i="21611" xml_f="21613" txt_i="14887" txt_f="14889">61</offsets></td><td><offsets xml_i="21622" xml_f="21624" txt_i="14890" txt_f="14892">93</offsets></td><td><offsets xml_i="21633" xml_f="21635" txt_i="14893" txt_f="14895">95</offsets></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="21686" xml_f="21689" txt_i="14896" txt_f="14899">a–b</offsets></sup><italic><offsets xml_i="21703" xml_f="21704" txt_i="14899" txt_f="14900">P</offsets></italic><offsets xml_i="21713" xml_f="21726" txt_i="14900" txt_f="14910"> &lt; 0.001, </offsets><sup><offsets xml_i="21731" xml_f="21734" txt_i="14910" txt_f="14913">a–c</offsets></sup><italic><offsets xml_i="21748" xml_f="21749" txt_i="14913" txt_f="14914">P</offsets></italic><offsets xml_i="21758" xml_f="21771" txt_i="14914" txt_f="14924"> &lt; 0.001, </offsets><sup><offsets xml_i="21776" xml_f="21779" txt_i="14924" txt_f="14927">b–c</offsets></sup><offsets xml_i="21785" xml_f="21801" txt_i="14927" txt_f="14943"> not significant</offsets></p></table-wrap-foot></table-wrap><fig id="Fig1"><label><offsets xml_i="21858" xml_f="21864" txt_i="14944" txt_f="14950">Fig. 1</offsets></label><caption><p><offsets xml_i="21884" xml_f="21973" txt_i="14950" txt_f="15039">A typical case of colorectal liver metastasis. In the T1-weighted images the metastasis (</offsets><italic><offsets xml_i="21981" xml_f="21992" txt_i="15039" txt_f="15050">black arrow</offsets></italic><offsets xml_i="22001" xml_f="22084" txt_i="15050" txt_f="15133">) has lower signal intensity compared to the surrounding parenchyma at all phases: </offsets><bold><offsets xml_i="22090" xml_f="22091" txt_i="15133" txt_f="15134">a</offsets></bold><offsets xml_i="22098" xml_f="22100" txt_i="15134" txt_f="15136">, </offsets><bold><offsets xml_i="22106" xml_f="22107" txt_i="15136" txt_f="15137">b</offsets></bold><offsets xml_i="22114" xml_f="22147" txt_i="15137" txt_f="15170"> before contrast administration, </offsets><bold><offsets xml_i="22153" xml_f="22154" txt_i="15170" txt_f="15171">c</offsets></bold><offsets xml_i="22161" xml_f="22235" txt_i="15171" txt_f="15245"> two hours after intravenous administration of gadobenate dimeglumine and </offsets><bold><offsets xml_i="22241" xml_f="22242" txt_i="15245" txt_f="15246">d</offsets></bold><offsets xml_i="22249" xml_f="22407" txt_i="15246" txt_f="15404"> three hours after oral ingestion of CMC-001. Some grade of enhancement of the lesion is observed after intravenous administration of gadobenate dimeglumine (</offsets><bold><offsets xml_i="22413" xml_f="22414" txt_i="15404" txt_f="15405">c</offsets></bold><offsets xml_i="22421" xml_f="22459" txt_i="15405" txt_f="15443">) but not after ingestion of CMC-001 (</offsets><bold><offsets xml_i="22465" xml_f="22466" txt_i="15443" txt_f="15444">d</offsets></bold><offsets xml_i="22473" xml_f="22480" txt_i="15444" txt_f="15451">). The </offsets><italic><offsets xml_i="22488" xml_f="22500" txt_i="15451" txt_f="15463">white arrows</offsets></italic><offsets xml_i="22509" xml_f="22532" txt_i="15463" txt_f="15486"> indicate liver vessels</offsets></p></caption><graphic xlink:href="330_2011_2288_Fig1_HTML" id="MO1"></graphic></fig><table-wrap id="Tab3"><label><offsets xml_i="22646" xml_f="22653" txt_i="15487" txt_f="15494">Table 3</offsets></label><caption><p><offsets xml_i="22673" xml_f="22695" txt_i="15494" txt_f="15516">False–positive lesions</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="22770" xml_f="22777" txt_i="15517" txt_f="15524">CMC-001</offsets></th><th><offsets xml_i="22786" xml_f="22808" txt_i="15524" txt_f="15546">Gadobenate dimeglumine</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="22841" xml_f="22844" txt_i="15546" txt_f="15549">FNH</offsets></td><td><offsets xml_i="22853" xml_f="22854" txt_i="15550" txt_f="15551">4</offsets><sup><offsets xml_i="22859" xml_f="22860" txt_i="15551" txt_f="15552">a</offsets></sup></td><td></td></tr><tr><td><offsets xml_i="22893" xml_f="22904" txt_i="15554" txt_f="15565">Haemangioma</offsets></td><td><offsets xml_i="22913" xml_f="22914" txt_i="15566" txt_f="15567">4</offsets></td><td></td></tr><tr><td><offsets xml_i="22941" xml_f="22961" txt_i="15569" txt_f="15589">Fibrotic haemangioma</offsets></td><td><offsets xml_i="22970" xml_f="22971" txt_i="15590" txt_f="15591">2</offsets></td><td><offsets xml_i="22980" xml_f="22981" txt_i="15592" txt_f="15593">2</offsets></td></tr><tr><td><offsets xml_i="22999" xml_f="23005" txt_i="15594" txt_f="15600">Vessel</offsets></td><td><offsets xml_i="23014" xml_f="23015" txt_i="15601" txt_f="15602">2</offsets></td><td></td></tr><tr><td><offsets xml_i="23042" xml_f="23064" txt_i="15604" txt_f="15626">Dysfunction/low uptake</offsets></td><td><offsets xml_i="23073" xml_f="23074" txt_i="15627" txt_f="15628">2</offsets><sup><offsets xml_i="23079" xml_f="23080" txt_i="15628" txt_f="15629">b</offsets></sup></td><td></td></tr><tr><td><offsets xml_i="23113" xml_f="23118" txt_i="15631" txt_f="15636">Clips</offsets></td><td><offsets xml_i="23127" xml_f="23128" txt_i="15637" txt_f="15638">1</offsets></td><td></td></tr><tr><td><offsets xml_i="23155" xml_f="23160" txt_i="15640" txt_f="15645">Total</offsets></td><td><offsets xml_i="23169" xml_f="23171" txt_i="15646" txt_f="15648">15</offsets></td><td><offsets xml_i="23180" xml_f="23181" txt_i="15649" txt_f="15650">2</offsets></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="23232" xml_f="23233" txt_i="15651" txt_f="15652">a</offsets></sup><offsets xml_i="23239" xml_f="23309" txt_i="15652" txt_f="15722">all focal nodular hyperplasias (FNH) were observed in the same patient</offsets></p><p><sup><offsets xml_i="23321" xml_f="23322" txt_i="15723" txt_f="15724">b</offsets></sup><offsets xml_i="23328" xml_f="23384" txt_i="15724" txt_f="15780">both false–positive lesions observed in the same patient</offsets></p></table-wrap-foot></table-wrap><fig id="Fig2"><label><offsets xml_i="23441" xml_f="23447" txt_i="15781" txt_f="15787">Fig. 2</offsets></label><caption><p><offsets xml_i="23467" xml_f="23518" txt_i="15787" txt_f="15838">A histopathologically proven fibrotic haemangioma (</offsets><italic><offsets xml_i="23526" xml_f="23531" txt_i="15838" txt_f="15843">arrow</offsets></italic><offsets xml_i="23540" xml_f="23641" txt_i="15843" txt_f="15944">) being falsely classified as metastasis on both gadobenate dimeglumine and CMC-001 enhanced MRI. In </offsets><bold><offsets xml_i="23647" xml_f="23648" txt_i="15944" txt_f="15945">a</offsets></bold><offsets xml_i="23655" xml_f="23740" txt_i="15945" txt_f="16030"> T2-HASTE image, the lesion is faintly hyperintense. In the T1-weighted images, both </offsets><bold><offsets xml_i="23746" xml_f="23747" txt_i="16030" txt_f="16031">b</offsets></bold><offsets xml_i="23754" xml_f="23809" txt_i="16031" txt_f="16086"> before and after injection of gadobenate dimeglumine (</offsets><bold><offsets xml_i="23815" xml_f="23816" txt_i="16086" txt_f="16087">c</offsets></bold><offsets xml_i="23823" xml_f="23834" txt_i="16087" txt_f="16098"> arterial, </offsets><bold><offsets xml_i="23840" xml_f="23841" txt_i="16098" txt_f="16099">d</offsets></bold><offsets xml_i="23848" xml_f="23867" txt_i="16099" txt_f="16118"> portal venous and </offsets><bold><offsets xml_i="23873" xml_f="23874" txt_i="16118" txt_f="16119">e</offsets></bold><offsets xml_i="23881" xml_f="23915" txt_i="16119" txt_f="16153"> hepatobiliary phases) as well as </offsets><bold><offsets xml_i="23921" xml_f="23922" txt_i="16153" txt_f="16154">f</offsets></bold><offsets xml_i="23929" xml_f="24048" txt_i="16154" txt_f="16273"> 3 h after ingestion of CMC-001, the lesion has low-signal intensity, being impossible to differentiate from metastasis</offsets></p></caption><graphic xlink:href="330_2011_2288_Fig2_HTML" id="MO2"></graphic></fig><fig id="Fig3"><label><offsets xml_i="24155" xml_f="24161" txt_i="16274" txt_f="16280">Fig. 3</offsets></label><caption><p><offsets xml_i="24181" xml_f="24234" txt_i="16280" txt_f="16333">A false–negative result for CMC-001 enhanced MRI. In </offsets><bold><offsets xml_i="24240" xml_f="24241" txt_i="16333" txt_f="16334">a</offsets></bold><offsets xml_i="24248" xml_f="24262" txt_i="16334" txt_f="16348"> T2-HASTE and </offsets><bold><offsets xml_i="24268" xml_f="24269" txt_i="16348" txt_f="16349">b</offsets></bold><offsets xml_i="24276" xml_f="24320" txt_i="16349" txt_f="16393"> unenhanced T1-weighted images, the lesion (</offsets><italic><offsets xml_i="24328" xml_f="24333" txt_i="16393" txt_f="16398">arrow</offsets></italic><offsets xml_i="24342" xml_f="24457" txt_i="16398" txt_f="16513">) is hardly discernible from an adjacent liver vessel. In the T1 images after injection of gadobenate dimeglumine (</offsets><bold><offsets xml_i="24463" xml_f="24464" txt_i="16513" txt_f="16514">c</offsets></bold><offsets xml_i="24471" xml_f="24482" txt_i="16514" txt_f="16525"> arterial, </offsets><bold><offsets xml_i="24488" xml_f="24489" txt_i="16525" txt_f="16526">d</offsets></bold><offsets xml_i="24496" xml_f="24515" txt_i="16526" txt_f="16545"> portal venous and </offsets><bold><offsets xml_i="24521" xml_f="24522" txt_i="16545" txt_f="16546">e</offsets></bold><offsets xml_i="24529" xml_f="24645" txt_i="16546" txt_f="16662"> hepatobiliary phases), the lesion has clearly lower signal intensity compared to the adjacent liver parenchyma. In </offsets><bold><offsets xml_i="24651" xml_f="24652" txt_i="16662" txt_f="16663">f</offsets></bold><offsets xml_i="24659" xml_f="24888" txt_i="16663" txt_f="16892"> the T1-weighted image 3 h after ingestion of CMC-001, the lesion is difficult to detect as it is situated in a part of the liver with decreased uptake of CMC-001 due to decreased portal perfusion and/or hepatobiliary dysfunction</offsets></p></caption><graphic xlink:href="330_2011_2288_Fig3_HTML" id="MO3"></graphic></fig><fig id="Fig4"><label><offsets xml_i="24995" xml_f="25001" txt_i="16893" txt_f="16899">Fig. 4</offsets></label><caption><p><offsets xml_i="25021" xml_f="25110" txt_i="16899" txt_f="16988">A false–negative result for gadobenate dimeglumine enhanced MRI (same patient as in Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="25142" xml_f="25143" txt_i="16988" txt_f="16989">3</offsets></xref><offsets xml_i="25150" xml_f="25165" txt_i="16989" txt_f="17004">). Both in the </offsets><bold><offsets xml_i="25171" xml_f="25172" txt_i="17004" txt_f="17005">a</offsets></bold><offsets xml_i="25179" xml_f="25275" txt_i="17005" txt_f="17101"> T2-HASTE image as well as in the T1-weighted images after injection of gadobenate dimeglumine (</offsets><bold><offsets xml_i="25281" xml_f="25282" txt_i="17101" txt_f="17102">c</offsets></bold><offsets xml_i="25289" xml_f="25300" txt_i="17102" txt_f="17113"> arterial, </offsets><bold><offsets xml_i="25306" xml_f="25307" txt_i="17113" txt_f="17114">d</offsets></bold><offsets xml_i="25314" xml_f="25333" txt_i="17114" txt_f="17133"> portal venous and </offsets><bold><offsets xml_i="25339" xml_f="25340" txt_i="17133" txt_f="17134">e</offsets></bold><offsets xml_i="25347" xml_f="25423" txt_i="17134" txt_f="17210"> hepatobiliary phases, the lesion is difficult to identify. However, in the </offsets><bold><offsets xml_i="25429" xml_f="25430" txt_i="17210" txt_f="17211">f</offsets></bold><offsets xml_i="25437" xml_f="25500" txt_i="17211" txt_f="17274"> T1-weighted image 3 h after ingestion of CMC-001, the lesion (</offsets><italic><offsets xml_i="25508" xml_f="25513" txt_i="17274" txt_f="17279">arrow</offsets></italic><offsets xml_i="25522" xml_f="25641" txt_i="17279" txt_f="17398">) has clearly lower signal intensity compared to the adjacent parenchyma allowing for correct diagnosis of a metastasis</offsets></p></caption><graphic xlink:href="330_2011_2288_Fig4_HTML" id="MO4"></graphic></fig><table-wrap id="Tab4"><label><offsets xml_i="25755" xml_f="25762" txt_i="17399" txt_f="17406">Table 4</offsets></label><caption><p><offsets xml_i="25782" xml_f="25955" txt_i="17406" txt_f="17579">Mean signal intensity (SI), of liver and metastases before and after contrast-medium administration. The SI is in arbitrary units (one standard deviation within parenthesis)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"></th><th colspan="2"><offsets xml_i="26054" xml_f="26061" txt_i="17580" txt_f="17587">CMC-001</offsets></th><th colspan="2"><offsets xml_i="26082" xml_f="26104" txt_i="17587" txt_f="17609">Gadobenate dimeglumine</offsets></th></tr><tr><th><offsets xml_i="26122" xml_f="26132" txt_i="17609" txt_f="17619">Unenhanced</offsets></th><th><offsets xml_i="26141" xml_f="26158" txt_i="17619" txt_f="17636">3 h post contrast</offsets></th><th><offsets xml_i="26167" xml_f="26177" txt_i="17636" txt_f="17646">Unenhanced</offsets></th><th><offsets xml_i="26186" xml_f="26203" txt_i="17646" txt_f="17663">2 h post contrast</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="26236" xml_f="26244" txt_i="17663" txt_f="17671">Liver SI</offsets></td><td char="(" align="char"><offsets xml_i="26275" xml_f="26283" txt_i="17672" txt_f="17680">160 (35)</offsets></td><td char="(" align="char"><offsets xml_i="26314" xml_f="26322" txt_i="17681" txt_f="17689">268 (91)</offsets><sup><offsets xml_i="26327" xml_f="26328" txt_i="17689" txt_f="17690">a</offsets></sup></td><td char="(" align="char"><offsets xml_i="26365" xml_f="26373" txt_i="17691" txt_f="17699">160 (37)</offsets></td><td char="(" align="char"><offsets xml_i="26404" xml_f="26412" txt_i="17700" txt_f="17708">267 (75)</offsets><sup><offsets xml_i="26417" xml_f="26418" txt_i="17708" txt_f="17709">b</offsets></sup></td></tr><tr><td><offsets xml_i="26442" xml_f="26455" txt_i="17710" txt_f="17723">Metastasis SI</offsets></td><td char="(" align="char"><offsets xml_i="26486" xml_f="26494" txt_i="17724" txt_f="17732">122 (27)</offsets></td><td char="(" align="char"><offsets xml_i="26525" xml_f="26533" txt_i="17733" txt_f="17741">122 (31)</offsets><sup><offsets xml_i="26538" xml_f="26539" txt_i="17741" txt_f="17742">c</offsets></sup></td><td char="(" align="char"><offsets xml_i="26576" xml_f="26584" txt_i="17743" txt_f="17751">127 (32)</offsets></td><td char="(" align="char"><offsets xml_i="26615" xml_f="26623" txt_i="17752" txt_f="17760">207 (53)</offsets><sup><offsets xml_i="26628" xml_f="26629" txt_i="17760" txt_f="17761">d</offsets></sup></td></tr><tr><td><offsets xml_i="26653" xml_f="26678" txt_i="17762" txt_f="17787">Metastasis to liver ratio</offsets></td><td char="(" align="char"><offsets xml_i="26709" xml_f="26720" txt_i="17788" txt_f="17799">0.22 (0.16)</offsets></td><td char="(" align="char"><offsets xml_i="26751" xml_f="26762" txt_i="17800" txt_f="17811">0.51 (0.17)</offsets><sup><offsets xml_i="26767" xml_f="26768" txt_i="17811" txt_f="17812">e</offsets></sup></td><td char="(" align="char"><offsets xml_i="26805" xml_f="26816" txt_i="17813" txt_f="17824">0.21 (0.15)</offsets></td><td char="(" align="char"><offsets xml_i="26847" xml_f="26858" txt_i="17825" txt_f="17836">0.21 (0.09)</offsets><sup><offsets xml_i="26863" xml_f="26864" txt_i="17836" txt_f="17837">f</offsets></sup></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="26921" xml_f="26924" txt_i="17838" txt_f="17841">a-b</offsets></sup><offsets xml_i="26930" xml_f="26945" txt_i="17841" txt_f="17856">not significant</offsets></p><p><sup><offsets xml_i="26957" xml_f="26960" txt_i="17857" txt_f="17860">c–d</offsets></sup><italic><offsets xml_i="26974" xml_f="26975" txt_i="17860" txt_f="17861">P</offsets></italic><offsets xml_i="26984" xml_f="26996" txt_i="17861" txt_f="17870"> &lt; 0.0001</offsets></p><p><sup><offsets xml_i="27008" xml_f="27011" txt_i="17871" txt_f="17874">e-f</offsets></sup><italic><offsets xml_i="27025" xml_f="27026" txt_i="17874" txt_f="17875">P</offsets></italic><offsets xml_i="27035" xml_f="27047" txt_i="17875" txt_f="17884"> &lt; 0.0001</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="27089" xml_f="27407" txt_i="17886" txt_f="18204">A total of 38 unique AE were reported in 19 patients. After CMC-001 administration, there were 31 AE reported (24 judged to be ADR) and after gadobenate dimeglumine, there were 9 AE reported (3 judged to be ADR). The number of patients with at least 1 AE was 19 after CMC-001 and 8 after gadobenate dimeglumine (Table </offsets><xref rid="Tab5" ref-type="table"><offsets xml_i="27441" xml_f="27442" txt_i="18204" txt_f="18205">5</offsets></xref><offsets xml_i="27449" xml_f="27999" txt_i="18205" txt_f="18755">). The most common AE were diarrhoea (12 AE in total, 12 after CMC-001 and 0 after gadobenate dimeglumine) and nausea (4 after CMC-001 and 2 after gadobenate dimeglumine). The most common ADR was diarrhoea (12 after CMC-001 and 0 after gadobenate dimeglumine) followed by supraventricular extrasystoles (1 after CMC-001 and 0 after gadobenate dimeglumine), back pain (1 after CMC-001 and 0 after gadobenate dimeglumine), headache (1 after CMC-001 and 0 after gadobenate dimeglumine) and urticaria (0 after CMC-001 and 1 after gadobenate dimeglumine).</offsets><table-wrap id="Tab5"><label><offsets xml_i="28028" xml_f="28035" txt_i="18755" txt_f="18762">Table 5</offsets></label><caption><p><offsets xml_i="28055" xml_f="28266" txt_i="18762" txt_f="18973">Total number of participants, number of participants with at least one adverse event (AE), adverse drug reactions (ADR)/number of AE, and intensity of AE for CMC-001 and gadobenate dimeglumine enhanced liver MRI</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="28341" xml_f="28348" txt_i="18974" txt_f="18981">CMC-001</offsets></th><th><offsets xml_i="28357" xml_f="28379" txt_i="18981" txt_f="19003">Gadobenate dimeglumine</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="28412" xml_f="28440" txt_i="19003" txt_f="19031">Total number of participants</offsets></td><td><offsets xml_i="28449" xml_f="28451" txt_i="19032" txt_f="19034">20</offsets></td><td><offsets xml_i="28460" xml_f="28462" txt_i="19035" txt_f="19037">20</offsets></td></tr><tr><td><offsets xml_i="28480" xml_f="28513" txt_i="19038" txt_f="19071">Participants with at least one AE</offsets></td><td char="(" align="char"><offsets xml_i="28544" xml_f="28552" txt_i="19072" txt_f="19080">19 (95%)</offsets></td><td><offsets xml_i="28561" xml_f="28568" txt_i="19081" txt_f="19088">8 (40%)</offsets></td></tr><tr><td><offsets xml_i="28586" xml_f="28602" txt_i="19089" txt_f="19105">Number of ADR/AE</offsets></td><td><offsets xml_i="28611" xml_f="28616" txt_i="19106" txt_f="19111">24/31</offsets></td><td><offsets xml_i="28625" xml_f="28628" txt_i="19112" txt_f="19115">3/9</offsets></td></tr><tr><td><offsets xml_i="28646" xml_f="28684" txt_i="19116" txt_f="19154">Intensity of AE (mild/moderate/severe)</offsets></td><td><offsets xml_i="28693" xml_f="28700" txt_i="19155" txt_f="19162">20/10/1</offsets></td><td><offsets xml_i="28709" xml_f="28714" txt_i="19163" txt_f="19168">7/2/0</offsets></td></tr></tbody></table></table-wrap></p><p><offsets xml_i="28760" xml_f="29175" txt_i="19170" txt_f="19585">The majority of adverse events were mild (20 AE after CMC-001 and 7 after gadobenate dimeglumine) or moderate (10 AE after CMC-001 and 2 after gadobenate dimeglumine). One AE (back pain judged to be possibly related to CMC-001) was recorded as severe in intensity. No serious AE were reported. There were no clinically significant changes in clinical laboratory changes, vital signs, ECG or at physical examination.</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="29208" xml_f="29218" txt_i="19587" txt_f="19597">Discussion</offsets></title><p><offsets xml_i="29229" xml_f="29553" txt_i="19598" txt_f="19922">The sensitivity to detect CRLM after orally administered manganese (93%) was comparable to that of intravenously administered gadobenate dimeglumine (95%). The high level of sensitivity concur with previously published studies on detection of liver metastases at MRI using intravenously administered mangafodipir trisodium [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="29586" xml_f="29588" txt_i="19922" txt_f="19924">13</offsets></xref><offsets xml_i="29595" xml_f="29625" txt_i="19924" txt_f="19954">] and gadobenate dimeglumine [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="29658" xml_f="29660" txt_i="19954" txt_f="19956">14</offsets></xref><offsets xml_i="29667" xml_f="29669" txt_i="19956" txt_f="19958">, </offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="29702" xml_f="29704" txt_i="19958" txt_f="19960">15</offsets></xref><offsets xml_i="29711" xml_f="30230" txt_i="19960" txt_f="20479">]. CRLM as small as 3 mm could be detected, regardless of which of the two liver-specific contrast agents was used. The novel contrast agent CMC-001 has, therefore, the potential to be used for surveillance of patients at high risk of liver metastases, distinguishing those cancer patients who need more extensive liver evaluation from those who do not. Such a group of patients are those with colorectal cancer. In this patient group liver metastases are present in up to 25% of the patients at the time of diagnosis [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="30263" xml_f="30265" txt_i="20479" txt_f="20481">16</offsets></xref><offsets xml_i="30272" xml_f="30309" txt_i="20481" txt_f="20518">] and in up to 50% five years later [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="30342" xml_f="30344" txt_i="20518" txt_f="20520">17</offsets></xref><offsets xml_i="30351" xml_f="30484" txt_i="20520" txt_f="20653">]. Patients who have undergone “curative” liver surgery for colorectal cancer metastases have a high recurrence rate, more than 60% [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="30517" xml_f="30519" txt_i="20653" txt_f="20655">18</offsets></xref><offsets xml_i="30526" xml_f="30956" txt_i="20655" txt_f="21085">]. Hence, patients with CRLM require follow up imaging for many years, preferentially with a fast and sensitive method. However, further studies assessing the effectiveness of CMC-001 enhanced liver MRI as a surveillance tool are required. An advantage of CMC-001 is that it allows patients to self-administer the contrast agent orally 2–3 h before the imaging acquisition session and obviating the need for intravenous injection.</offsets></p><p><offsets xml_i="30963" xml_f="31438" txt_i="21086" txt_f="21561">There were 15 false–positive results at the CMC-001 session compared with 2 false–positive results at the gadobenate dimeglumine session. This higher false–positive rate is a downside of CMC-001 compared to gadobenate dimeglumine-enhanced liver MRI, where additional information about the contrast behavior of lesions is obtained at the dynamic phase after contrast injection, resulting in higher specificity. In clinical practice, this means that when lesions are detected a</offsets></p><p><offsets xml_i="31445" xml_f="31670" txt_i="21562" txt_f="21787">When comparing the signal intensity of the liver parenchyma before and after contrast-medium administration, there was no difference in the signal increase after CMC-001 compared with that after gadobenate dimeglumine (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="31704" xml_f="31705" txt_i="21787" txt_f="21788">4</offsets></xref><offsets xml_i="31712" xml_f="32146" txt_i="21788" txt_f="22222">). However, the metastases did also show some grade of enhancement after gadobenate dimeglumine, but not after CMC-001. Thus, there was a significant increase in the metastasis-to-liver ratio after CMC-001, but not after gadobenate dimeglumine. In the present study, the sensitivity to detect CRLM on T1-weighted images without contrast media was low (61%), which is much lower compared with previously published data by Choi et al. [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="32179" xml_f="32181" txt_i="22222" txt_f="22224">15</offsets></xref><offsets xml_i="32188" xml_f="32801" txt_i="22224" txt_f="22837">] with sensitivity of 86% before and 96% after gadobenate dimeglumine. One possible explanation for their greater sensitivity before contrast media were administered can be the fact that the readers in Choi’s study also had access to T2-weighted images, while in our study readers evaluated only T1-weighted images at the unenhanced session. Interestingly, their sensitivity increased only to 87% when adding the dynamic phases after gadobenate dimeglumine injection (excluding the hepatobiliary phase), and the number of false–positive lesions increased from 0 to 1. Furthermore, published data from Kim et al. [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="32834" xml_f="32836" txt_i="22837" txt_f="22839">14</offsets></xref><offsets xml_i="32843" xml_f="33192" txt_i="22839" txt_f="23188">] show that the hepatobiliary (one-hour delayed) phase had a better diagnostic performance than the dynamic phase imaging after gadobenate dimeglumine injection for the detection of liver metastases (sensitivity of 96% and 77%, respectively). These findings indicate that the hepatobiliary phase can play an important role in the evaluation of CRLM.</offsets></p><p><offsets xml_i="33199" xml_f="33522" txt_i="23189" txt_f="23512">The dominant excretion of manganese via the hepatobiliary pathway makes it theoretically attractive for use in patients with impaired renal function. When measuring manganese levels in blood levels and urine in healthy volunteers after ingestion of CMC-001, no significant increase in manganese concentration was detected [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="33555" xml_f="33557" txt_i="23512" txt_f="23514">19</offsets></xref><offsets xml_i="33564" xml_f="33653" txt_i="23514" txt_f="23603">]. Further safety studies are, however, needed before such recommendations can be issued.</offsets></p><p><offsets xml_i="33660" xml_f="34038" txt_i="23604" txt_f="23982">There were no serious AE. All but one of the AE were considered by the investigator to be of mild or moderate intensity and no safety concerns were raised for any of the two products. The observed adverse events were related to the high ion-content resulting in gastrointestinal discomfort, diarrhoea and nausea. We are therefore currently examining if lowering the dose of MnCl</offsets><sub><offsets xml_i="34043" xml_f="34044" txt_i="23982" txt_f="23983">2</offsets></sub><offsets xml_i="34050" xml_f="34423" txt_i="23983" txt_f="24356"> tetrahydrate can result in fewer AE but with a sufficient diagnostic imaging quality. Apart from the gastrointestinal disorders, a limitation of using CMC-001 can be the inhomogeneous uptake in cases of low portal venous perfusion and/or of decreased liver function increasing the risk for suboptimal enhancement and diminishing lesion conspicuity (as is the case in Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="34455" xml_f="34456" txt_i="24356" txt_f="24357">3</offsets></xref><offsets xml_i="34463" xml_f="34465" txt_i="24357" txt_f="24359">).</offsets></p><p><offsets xml_i="34472" xml_f="35289" txt_i="24360" txt_f="25177">In our study, all patients were evaluated for liver surgery. Therefore, a majority of the metastases (25/44) could be verified at histopathology. However, the remaining 19 lesions were not considered resectable and therefore they lack histopathological verification. The final diagnosis of these had to rely on other imaging studies and on follow up. This is a limitation of our study and a factor for potential bias and overestimation of sensitivity. Additionally, our patient cohort, i.e. those with colorectal cancer and high risk of having liver metastases, comprise a highly selected study population, potentially also contributing to an overestimation of sensitivity. However, these limitations are considered to be of low impact in the present comparison with the comprehensive gadobenate dimeglumine protocol.</offsets></p><p><offsets xml_i="35296" xml_f="35534" txt_i="25178" txt_f="25416">In conclusion, the sensitivity to detect colorectal cancer liver metastases at CMC-001 enhanced MRI is comparably high to that of a comprehensive intravenous gadobenate dimeglumine protocol; and it is safe, without serious adverse events.</offsets></p></sec></body><back><ack><title>Acknowledgements</title><p>N.A. is a consultant for CMC Medical, the company who financed the clinical trial.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">The Royal College of Radiologists (2007) RCR Referral Guidelines: Making the best use of clinical radiology services (MBUR), 6th Edition. London, pp 96–97</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schima</surname><given-names>W</given-names></name><name><surname>Kulinna</surname><given-names>C</given-names></name><name><surname>Langenberger</surname><given-names>H</given-names></name><name><surname>Ba-Ssalamah</surname><given-names>A</given-names></name></person-group><article-title>Liver metastases of colorectal cancer: US, CT or MR</article-title><source>Cancer Imaging</source><year>2005</year><volume>5</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1102/1470-7330.2005.0035</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konopke</surname><given-names>R</given-names></name><name><surname>Bunk</surname><given-names>A</given-names></name><name><surname>Kersting</surname><given-names>S</given-names></name></person-group><article-title>The role of contrast-enhanced ultrasound for focal liver lesion detection: an overview</article-title><source>Ultrasound Med Biol</source><year>2007</year><volume>33</volume><fpage>1515</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1016/j.ultrasmedbio.2007.04.009</pub-id><pub-id pub-id-type="pmid">17618038</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niekel</surname><given-names>MC</given-names></name><name><surname>Bipat</surname><given-names>S</given-names></name><name><surname>Stoker</surname><given-names>J</given-names></name></person-group><article-title>Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment</article-title><source>Radiology</source><year>2010</year><volume>257</volume><fpage>674</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1148/radiol.10100729</pub-id><pub-id pub-id-type="pmid">20829538</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DR</given-names></name><name><surname>Danrad</surname><given-names>R</given-names></name><name><surname>Hussain</surname><given-names>SM</given-names></name></person-group><article-title>MR imaging of the liver</article-title><source>Radiol Clin North Am</source><year>2005</year><volume>43</volume><fpage>861</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1016/j.rcl.2005.05.001</pub-id><pub-id pub-id-type="pmid">16098344</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>HS</given-names></name></person-group><article-title>Recent hot topics in contrast media</article-title><source>Eur Radiol</source><year>2011</year><volume>21</volume><fpage>492</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1007/s00330-010-2026-x</pub-id><pub-id pub-id-type="pmid">21136062</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chabanova</surname><given-names>E</given-names></name><name><surname>Logager</surname><given-names>V</given-names></name><name><surname>Moller</surname><given-names>JM</given-names></name><name><surname>Dekker</surname><given-names>H</given-names></name><name><surname>Barentsz</surname><given-names>J</given-names></name><name><surname>Thomsen</surname><given-names>HS</given-names></name></person-group><article-title>Imaging liver metastases with a new oral manganese-based contrast agent</article-title><source>Acad Radiol</source><year>2006</year><volume>13</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.acra.2006.03.013</pub-id><pub-id pub-id-type="pmid">16777556</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>M</given-names></name><name><surname>Huppertz</surname><given-names>A</given-names></name><name><surname>Asbach</surname><given-names>P</given-names></name><name><surname>Franiel</surname><given-names>T</given-names></name><name><surname>Schwenke</surname><given-names>C</given-names></name><name><surname>Hamm</surname><given-names>B</given-names></name><name><surname>Taupitz</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name></person-group><article-title>Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement</article-title><source>Invest Radiol</source><year>2010</year><volume>45</volume><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1097/RLI.0b013e3181e9e120</pub-id><pub-id pub-id-type="pmid">20644484</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>CD</given-names></name><name><surname>Zech</surname><given-names>L</given-names></name><name><surname>Greger</surname><given-names>JL</given-names></name></person-group><article-title>Manganese metabolism in rats: an improved methodology for assessing gut endogenous losses</article-title><source>Proc Soc Exp Biol Med</source><year>1993</year><volume>202</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">8424090</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malecki</surname><given-names>EA</given-names></name><name><surname>Radzanowski</surname><given-names>GM</given-names></name><name><surname>Radzanowski</surname><given-names>TJ</given-names></name><name><surname>Gallaher</surname><given-names>DD</given-names></name><name><surname>Greger</surname><given-names>JL</given-names></name></person-group><article-title>Biliary manganese excretion in conscious rats is affected by acute and chronic manganese intake but not by dietary fat</article-title><source>J Nutr</source><year>1996</year><volume>126</volume><fpage>489</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">8632223</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finley</surname><given-names>JW</given-names></name><name><surname>Johnson</surname><given-names>PE</given-names></name><name><surname>Johnson</surname><given-names>LK</given-names></name></person-group><article-title>Sex affects manganese absorption and retention by humans from a diet adequate in manganese</article-title><source>Am J Clin Nutr</source><year>1994</year><volume>60</volume><fpage>949</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">7985639</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seale</surname><given-names>MK</given-names></name><name><surname>Catalano</surname><given-names>OA</given-names></name><name><surname>Saini</surname><given-names>S</given-names></name><name><surname>Hahn</surname><given-names>PF</given-names></name><name><surname>Sahani</surname><given-names>DV</given-names></name></person-group><article-title>Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree</article-title><source>Radiographics</source><year>2009</year><volume>29</volume><fpage>1725</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1148/rg.296095515</pub-id><pub-id pub-id-type="pmid">19959518</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolozzi</surname><given-names>C</given-names></name><name><surname>Donati</surname><given-names>F</given-names></name><name><surname>Cioni</surname><given-names>D</given-names></name><name><surname>Procacci</surname><given-names>C</given-names></name><name><surname>Morana</surname><given-names>G</given-names></name><name><surname>Chiesa</surname><given-names>A</given-names></name><name><surname>Grazioli</surname><given-names>L</given-names></name><name><surname>Cittadini</surname><given-names>G</given-names></name><name><surname>Cittadini</surname><given-names>G</given-names></name><name><surname>Giovagnoni</surname><given-names>A</given-names></name><name><surname>Gandini</surname><given-names>G</given-names></name><name><surname>Maass</surname><given-names>J</given-names></name><name><surname>Lencioni</surname><given-names>R</given-names></name></person-group><article-title>Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT</article-title><source>Eur Radiol</source><year>2004</year><volume>14</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00330-003-1966-9</pub-id><pub-id pub-id-type="pmid">14730384</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Chung</surname><given-names>GH</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name><name><surname>Kim</surname><given-names>IH</given-names></name></person-group><article-title>Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging</article-title><source>Eur Radiol</source><year>2005</year><volume>15</volume><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1007/s00330-004-2570-3</pub-id><pub-id pub-id-type="pmid">15624108</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Choi</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Chung</surname><given-names>YE</given-names></name></person-group><article-title>Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent</article-title><source>J Magn Reson Imaging</source><year>2010</year><volume>31</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1002/jmri.22076</pub-id><pub-id pub-id-type="pmid">20187199</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manfredi</surname><given-names>S</given-names></name><name><surname>Lepage</surname><given-names>C</given-names></name><name><surname>Hatem</surname><given-names>C</given-names></name><name><surname>Coatmeur</surname><given-names>O</given-names></name><name><surname>Faivre</surname><given-names>J</given-names></name><name><surname>Bouvier</surname><given-names>AM</given-names></name></person-group><article-title>Epidemiology and management of liver metastases from colorectal cancer</article-title><source>Ann Surg</source><year>2006</year><volume>244</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000217629.94941.cf</pub-id><pub-id pub-id-type="pmid">16858188</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengmark</surname><given-names>S</given-names></name><name><surname>Hafström</surname><given-names>L</given-names></name></person-group><article-title>The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy</article-title><source>Cancer</source><year>1969</year><volume>23</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(196901)23:1&lt;198::AID-CNCR2820230126&gt;3.0.CO;2-J</pub-id><pub-id pub-id-type="pmid">5763253</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jong</surname><given-names>MC</given-names></name><name><surname>Pulitano</surname><given-names>C</given-names></name><name><surname>Ribero</surname><given-names>D</given-names></name><name><surname>Strub</surname><given-names>J</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><name><surname>Schulick</surname><given-names>RD</given-names></name><name><surname>Choti</surname><given-names>MA</given-names></name><name><surname>Aldrighetti</surname><given-names>L</given-names></name><name><surname>Capussotti</surname><given-names>L</given-names></name><name><surname>Pawlik</surname><given-names>TM</given-names></name></person-group><article-title>Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients</article-title><source>Ann Surg</source><year>2009</year><volume>250</volume><fpage>440</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">19730175</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>HS</given-names></name><name><surname>Loegager</surname><given-names>V</given-names></name><name><surname>Noergaard</surname><given-names>H</given-names></name><name><surname>Chabanova</surname><given-names>E</given-names></name><name><surname>Moller</surname><given-names>JM</given-names></name><name><surname>Sonne</surname><given-names>J</given-names></name></person-group><article-title>Oral manganese for liver imaging at three different field strengths</article-title><source>Acad Radiol</source><year>2004</year><volume>11</volume><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.acra.2004.01.004</pub-id><pub-id pub-id-type="pmid">15172365</pub-id></mixed-citation></ref></ref-list></back></article>